Merck Licenses Ingenuity Pathways Analysis Software

Dec 06, 2004

NEW YORK, Dec. 6 (GenomeWeb News) - Merck has taken a multi-year license to Ingenuity's Pathways Analysis software for use by its scientists worldwide, the companies said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Johns Hopkins Researcher Awarded $300K From ALCF to Investigate Genetics of Lung Cancer
St. Jude Children's Research Hospital, RPRD Diagnostics Partner to Offer Pharmacogenetic Testing
Fabric Genomics Announces Multiple Pediatric Medicine Initiatives; Edico Genome Partnership
Meridian Bioscience Preliminary FY2017 Revenues Beat Estimates
Clinical Genomics, MSKCC to Study Rectal Cancer Liquid Biopsy Monitoring
Danaher Q3 Revenues Rise 10 Percent

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Main menu